Polycythemia Vera
📧 Sign up to get email alerts when something new happens for Polycythemia Vera.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-10-21Clinical Trial Update: Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera [Phase 2]
This update reports on the efficacy and safety outcomes of pegylated interferon alfa in polycythemia vera from a Phase 2 trial that has comp…
-
CLINICAL_TRIALS trial_result · 2015-10-08Clinical Trial Update: Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis [Phase 2]
A Phase 2 open-label trial of oral CEP-701 (lestaurtinib) in Polycythemia Vera and Essential Thrombocythemia has completed.
-
FDA approval · 2015-10-06FDA Approved: JAKAFI — Supplemental Application (Incyte Corporation)
The FDA approved a supplemental application for Jakafi (ruxolitinib) submitted by Incyte Corporation, resulting in labeling updates.
-
CLINICAL_TRIALS research · 2015-10-01Clinical Trial Update: Natural Killer Cells and Polycythemia Vera (Vaquez's Disease)
An update on a clinical trial investigating natural killer cells in patients with polycythemia vera (Vaquez's disease).
-
CLINICAL_TRIALS trial_result · 2015-08-21Clinical Trial Update: A Phase 1 Study of XL019 in Adults With Polycythemia Vera [Phase 1]
The Phase 1 study XL019 in adults with Polycythemia Vera has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-04-07Clinical Trial Update: Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study [Phase 3]
Phase 3 randomized trial evaluating switching from hydroxyurea to ruxolitinib for relief of polycythemia vera symptoms; results were posted …
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) [Phase 3]
Phase 3 study comparing a JAK inhibitor INC424 (ruxolitinib) to best available care in hydroxyurea-resistant or -intolerant polycythemia ver…
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: LBH589 (Panobinostat) for the Treatment of Myelofibrosis [Phase 1, Phase 2]
Phase 1/Phase 2 clinical trial update for LBH589 (panobinostat) in myelofibrosis with current status not reported.
-
FDA approval · 2014-12-15FDA Approved: JAKAFI — Supplemental Application (Incyte Corporation)
The FDA announced a supplemental application submission for JAKAFI (ruxolitinib) by Incyte, indicating a potential supplemental approval. Th…
-
CLINICAL_TRIALS research · 2014-11-26Clinical Trial Update: CEP-701 (Lestaurtinib) in Myelofibrosis [Phase 1, Phase 2]
Clinical trial update on CEP-701 (lestaurtinib) in myelofibrosis, with additional conditions essential thrombocythemia and polycythemia vera…
-
CLINICAL_TRIALS withdrawal · 2014-11-26Clinical Trial Update: Clopidogrel and Aspirin for the Treatment of Polycythemia Vera [Phase 2]
A Phase 2 clinical trial investigating the combination of clopidogrel and aspirin for polycythemia vera was withdrawn.
-
CLINICAL_TRIALS trial_result · 2014-10-08Clinical Trial Update: Effects of Imatinib Mesylate in Polycythemia Vera [Phase 2]
A Phase 2 study evaluating imatinib mesylate in polycythemia vera has completed, with results summarized in this update.
-
CLINICAL_TRIALS trial_result · 2014-08-28Clinical Trial Update: Anti-TGF-beta Therapy in Patients With Myelofibrosis [Phase 1]
Phase 1 trial evaluating an anti-TGF-beta therapy in myelofibrosis was terminated; results were posted in 2014.
-
FDA approval · 2014-05-30FDA Approved: JAKAFI — Supplemental Application (Incyte Corporation)
The FDA approved a supplemental application for JAKAFI (ruxolitinib) submitted by Incyte Corporation, resulting in updated labeling.
-
CLINICAL_TRIALS trial_result · 2014-05-21Clinical Trial Update: 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia [Phase 2]
Phase 2 trial evaluating the combination of Triapine (3-AP) and fludarabine in various myeloproliferative disorders and advanced phases of c…
-
CLINICAL_TRIALS trial_result · 2014-02-25Clinical Trial Update: Imatinib Mesylate in Treating Patients With Myelofibrosis [Phase 2]
Phase 2 clinical trial evaluating Imatinib Mesylate in patients with myelofibrosis has completed. The study also addresses related myeloprol…
-
CLINICAL_TRIALS trial_result · 2013-09-26Clinical Trial Update: Lenalidomide and Prednisone in Treating Patients With Myelofibrosis [Phase 2]
This Phase 2 trial evaluated lenalidomide in combination with prednisone for patients with myelofibrosis and related myeloproliferative neop…
-
CLINICAL_TRIALS trial_result · 2013-06-17Clinical Trial Update: Plasma Vitamin and Homocysteine Levels and Thrombosis in Patients With Ph-negative MPNs
This clinical trial update reports on plasma vitamin and homocysteine levels and thrombosis in patients with Philadelphia-negative myeloprol…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia [Phase 2]
Phase 2 clinical trial update on tipifarnib for myelofibrosis and related myeloproliferative disorders, with the study having completed.
-
CLINICAL_TRIALS research · 2013-03-21Clinical Trial Update: Myeloproliferative Neoplasms and Bone Structure
This is a clinical trial update on myeloproliferative neoplasms and bone structure. The current status of the study is unknown.
-
CLINICAL_TRIALS trial_result · 2012-08-02Clinical Trial Update: Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis [Phase 1, Phase 2]
Open-label Phase 1/2 trial results for ruxolitinib (INCB018424) in patients with myelofibrosis, including those with post-polycythemia vera/…
-
CLINICAL_TRIALS withdrawal · 2012-07-20Clinical Trial Update: Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) [Phase 3]
A large Phase 3 trial evaluating the intensity of cytoreductive therapy in polycythemia vera has been terminated.
-
FDA approval · 2012-06-21FDA Approved: JAKAFI — Supplemental Application (Incyte Corporation)
The FDA approved a supplemental application for JAKAFI (ruxolitinib) submitted by Incyte Corporation.
-
CLINICAL_TRIALS trial_result · 2012-04-20Clinical Trial Update: A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis [Phase 1, Phase 2]
The Phase 1/2 study of oral SB1518 (pacritinib) in chronic idiopathic myelofibrosis has completed, with the trial listing other myeloprolife…
-
CLINICAL_TRIALS trial_result · 2012-02-24Clinical Trial Update: Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia [Phase 2]
Phase 2 study of ruxolitinib (INCB018424) in polycythemia vera and essential thrombocythemia was terminated, with results posted in 2012.